180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in ...

PALO ALTO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company announced that the first patient

Related Keywords

United States ,United Kingdom ,America ,British ,Marc Feldmann ,Jason Assad ,Sally Hopewell ,National Institute Of Health ,University Of Oxford ,Life Sciences Corp ,Suzanne Messere Stern Investor Relations Inc ,Nasdaq ,Exchange Commission ,National Institute For Health ,Department Of Health ,Oxford Clinical Trials Research Unit ,Life Sciences ,Care Research ,James Woody ,Chief Executive Officer ,National Institute ,Professor Nanchahal ,Professor Sally Hopewell ,Sir Marc Feldmann ,Executive Co Chairman ,United Kingdom Aid ,Private Securities Litigation Reform Act ,Investigational New Drug ,Annual Report ,Quarterly Report ,Jason Assad Director ,Sciences Corp ,Messere Stern Investor Relations ,National Academy ,Anti Tumour Necrosis Factor Therapy ,Randomised Dose Response Proof ,Concept Phase ,Early Stage Dupuytren ,Lancet Rheumatology ,British Medical Journal ,Database Syst Rev ,Cochrane Database Syst Rev ,Money ,Ational ,